CD30-Positive Lymphoproliferative Disorders

Cancer Treat Res. 2019:176:249-268. doi: 10.1007/978-3-319-99716-2_12.

Abstract

Primary cutaneous CD30-positive lymphoproliferative disorders (CD30+ LPD) encompass lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (pcALCL), and borderline lesions [1]. CD30+ LPD are the second most common cutaneous T-cell lymphomas (CTCL) after mycosis fungoides (MF) and represent approximately 25% of all CTCL cases [2]. Their common phenotypic hallmark is an expression of the CD30 antigen, a cytokine receptor belonging to the tumor necrosis factor (TNF) receptor superfamily. Both LyP and pcALCL show numerous clinical, histological and immunophenotypic variants, and generally have an indolent course with a favorable prognosis. Overlapping features of LyP and pcALCL with other CD30+ T-cell lymphomas, inflammatory, and/or infectious conditions emphasize the importance of careful clinicopathologic correlation and staging.

Keywords: Borderline lesions; CD30+ lymphoproliferative disorder; Cutaneous T-cell lymphoma; Extensive limb disease; Lymphomatoid papulosis; Primary cutaneous anaplastic large cell lymphoma; Therapeutic targets.

MeSH terms

  • Adult
  • Humans
  • Immunophenotyping
  • Ki-1 Antigen
  • Lymphomatoid Papulosis* / diagnosis
  • Lymphomatoid Papulosis* / therapy
  • Lymphoproliferative Disorders* / diagnosis
  • Lymphoproliferative Disorders* / immunology
  • Lymphoproliferative Disorders* / therapy
  • Mycosis Fungoides* / diagnosis
  • Mycosis Fungoides* / therapy
  • Skin Neoplasms* / diagnosis
  • Skin Neoplasms* / therapy

Substances

  • Ki-1 Antigen